Tesamorelin: GHRH Analogue for Fat Loss and Growth Hormone Research

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that signals the pituitary gland to secrete growth hormone (GH). Unlike exogenous GH or GH secretagogues that act at the pituitary directly, tesamorelin works upstream, preserving the pulsatile, physiological pattern of GH release.

FDA Approval and Clinical Background

Tesamorelin (brand name Egrifta) holds FDA approval for the reduction of excess abdominal fat in HIV-positive individuals with lipodystrophy. This makes it one of a handful of peptides with a robust human clinical trial dataset and an approved medical application — a meaningful distinction from most research peptides.

The approval is based on Phase 3 data showing:

• ·Significant visceral adipose tissue (VAT) reduction — approximately 15–18% over 26 weeks in the primary trials
• ·Improved lipid profiles — reductions in triglycerides and improvements in cholesterol ratios
• ·Preserved glucose homeostasis — unlike exogenous GH, tesamorelin's physiological pulsatility avoids sustained insulin resistance

Mechanism of Action

Tesamorelin binds GHRH receptors in the anterior pituitary, triggering GH release in pulses that mimic the body's natural secretion pattern. This elevated GH then stimulates IGF-1 production in the liver, which mediates many of GH's downstream effects:

• ·Lipolysis (fat breakdown), particularly in visceral adipose deposits
• ·Lean tissue preservation
• ·Improved lipid metabolism
• ·Potential collagen synthesis support

Because tesamorelin stimulates endogenous GH rather than replacing it, the hypothalamic-pituitary-adrenal feedback loop remains intact. This is why tesamorelin's glucose effects are less pronounced than direct GH injection at equivalent GH output.

Research Applications

Beyond its approved indication, researchers are studying tesamorelin for:

• ·Cognitive function — a notable 2019 study in JAMA Internal Medicine found tesamorelin improved cognitive performance in older adults with mild cognitive impairment
• ·Non-alcoholic fatty liver disease (NAFLD) — GH deficiency is associated with hepatic fat accumulation; tesamorelin's GH stimulation is being studied as an intervention
• ·General body composition research — the VAT-selective fat reduction profile makes it of interest for metabolic studies beyond the HIV context

Reconstitution and Handling

Tesamorelin is relatively sensitive compared to smaller peptides. Reconstitute with sterile water for injection rather than bacteriostatic water per manufacturer guidance for the pharmaceutical product. Refrigerate reconstituted solution and use within 21 days.

Lyophilized tesamorelin should be stored at -20°C and protected from light and moisture.

View the Tesamorelin Research Protocol for detailed dosing tables and reconstitution guidance. Shop Tesamorelin or explore the Recomposition Protocol for a broader body composition research framework.

Note: Tesamorelin is sold by JA Performance strictly for laboratory and in vitro research use. Not for human consumption.